How to merge Roche and Genentech

Want a primer on the legal ins and outs of Roche's bid for Genentech? We don't blame you. Between state and federal laws and the two companies' own affiliation agreement, the deal could get pretty complicated. Luckily, DealBook has obliged. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.